37th Annual Report FY2425

Rekvina Laboratories reported zero revenue from operations for the second consecutive year (FY24-25 and FY23-24), blaming an overall economic slowdown. The company incurred a loss during the year, with total expenditure of Rs. 4.28 lakhs against nil income. No dividend has been recommended. The equity shares remain suspended from trading on BSE due to non-compliance with SEBI LODR regulations; an application for revocation was filed in November 2024 and is still under process. Several board changes occurred during the year - a new Managing Director, Executive Director & CFO, Company Secretary, and Independent Directors were appointed, while Vice Chairman Mr. Mukesh Jamnadas Shah passed away in June 2024. The statutory auditor was changed mid-year to M/s Y.M. Shah & Co. (appointed 2 September 2024) after the previous auditor completed two consecutive 5-year terms. The Secretarial Auditor flagged multiple compliance lapses including website disclosures, delayed ROC filings, and Structured Digital Database (SDD) related issues, for which the Board has assured corrective action. The company has no subsidiaries, no manufacturing activity, and no foreign exchange transactions.